title: [Guidelines for the management of ulcerative colitis].
abstract: Ulcerative colitis (UC) is a chronic inflammatory bowel disorder characterized by a relapsing and remitting course. The quality of life can decreases significantly during exacerbations of the disease. The incidence and prevalence of UC in Korea are still lower than those of Western countries, but have been rapidly increasing during the past decades. Various medical and surgical therapies are currently used for the management of UC. However, many challenging issues exist and sometimes these lead to differences in practice between clinicians. Therefore, Inflammatory Bowel Diseases (IBD) Study Group of Korean Association for the Study of Intestinal Diseases (KASID) set out the Korean guidelines for the management of UC. These guidelines are made by the adaptation using several foreign guidelines and encompass treatment of active colitis, maintenance of remission and indication for surgery in UC. The specific recommendations are presented with the quality of evidence. These are the first Korean treatment guidelines for UC and will be revised with new evidences on treatment of UC.
authors.affiliation: Department of Internal Medicine, Chung-Ang University College of Medicine, Korea.
authors.forename: Chang Hwan
authors.initials: CH
authors.lastname: Choi
authors.forename: Young-Ho
authors.initials: YH
authors.lastname: Kim
authors.forename: You Sun
authors.initials: YS
authors.lastname: Kim
authors.forename: Byong Duk
authors.initials: BD
authors.lastname: Ye
authors.forename: Kang Moon
authors.initials: KM
authors.lastname: Lee
authors.forename: Bo In
authors.initials: BI
authors.lastname: Lee
authors.forename: Sung-Ae
authors.initials: SA
authors.lastname: Jung
authors.forename: Won Ho
authors.initials: WH
authors.lastname: Kim
authors.forename: Heeyoung
authors.initials: H
authors.lastname: Lee
mesh_terms: D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D000069285:Infliximab; D007275:Injections, Intravenous; D019804:Mesalamine / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D012720:Severity of Illness Index; D012460:Sulfasalazine / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000964:Antimetabolites, Antineoplastic; D012460:Sulfasalazine; D019804:Mesalamine; D000069285:Infliximab; D001379:Azathioprine; D006854:Hydrocortisone; D008775:Methylprednisolone